lohud.com

Sponsored by:

Business in the Burbs

Movers, shakers and newsmakers

Progenics stock rises on drug trial news

May
22

Progenics Pharmaceuticals Inc. of Eastview and its research partner, Wyeth Pharmaceuticals, announced good and bad news concerning drug trials on its treatment for side effects of painkillers. Investors focused on the positive, and Progenics stock rose 9.79 percent today.
The companies said that a phase 2 study of an oral form of its Relistor drug for the treatment of constipation showed statistically significant improvements in patients. A phase 3 study of an intravenous form of Relistor on post-operative gastrointestinal function, however, fell short of research goals.
Progenics stock closed at $14.47, up $1.29.

This entry was posted on Thursday, May 22nd, 2008 at 4:17 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: del.icio.us Digg | Print Print | Email Email

Advertisement

Leave a Reply

About this blog
Business in the Burbs is our online news blog about businesses based or operating in the Lower Hudson Valley. Visitors here will also find items of interest to consumers in the region. Most contributions are from business reporters and editors covering Westchester, Rockland and Putnam counties.

Enter your email address to get daily updates from Business in the Burbs sent to your inbox:

About the Authors

Categories

Other recent entries


Latest LoHud Business news


Links

Monthly Archives